Legal & General Group
ACHL

Legal & General Group’s Achilles Therapeutics ACHL Stock Holding History

Legal & General Group’s Portfolio ACHL Stock Details ACHL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-24,755
Closed -$72K – 3686
2022
Q1 		$72K Hold
24,755
– – ﹤0.01% 2936
2021
Q4 		$124K Buy
+24,755
New +$150K ﹤0.01% 2864
2021
Q2 		– Sell
-5,000
Closed -$83K – 3676
2021
Q1 		$83K Buy
+5,000
New +$82.8K ﹤0.01% 2666

Other funds holding ACHL

SP
Syncona Portfolio St Peter Port, Guernsey $25.7M AUM 13.32% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KHCM
Kettle Hill Capital Management New York $399M AUM 10.05% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Legal & General Group's ACHL Position: Q2 2022 in Review

Legal & General Group sold out of Achilles Therapeutics (ACHL) in Q2 2022, closing a stake of 24,755 shares — an estimated $72K sold.

Legal & General Group first reported a position in ACHL in Q1 2021 and held it in 3 quarters. The position peaked at $124K in Q4 2021. 25 funds tracked by Wall St. Rank hold ACHL as of Q2 2022.

  • Legal & General Group reported no remaining Achilles Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Legal & General Group sold 24,755 Achilles Therapeutics shares in Q2 2022, an estimated $72K.
  • Legal & General Group first reported a position in Achilles Therapeutics in Q1 2021 and held it in 3 quarters.
  • Legal & General Group's Achilles Therapeutics position peaked at $124K in Q4 2021.
  • 25 funds tracked by Wall St. Rank held Achilles Therapeutics as of Q2 2022.

Based on Legal & General Group's 13F filing for Q2 2022, filed 22 Aug 2022.